- Home
- LILA vs AUPH Comparison
LILA vs AUPH Comparison
Compare LILA & AUPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LILA
- AUPH
- Stock Information
- Founded
- LILA 2017
- AUPH 1993
- Country
- LILA Bermuda
- AUPH Canada
- Employees
- LILA N/A
- AUPH N/A
- Industry
- LILA Cable & Other Pay Television Services
- AUPH Biotechnology: Pharmaceutical Preparations
- Sector
- LILA Telecommunications
- AUPH Health Care
- Exchange
- LILA Nasdaq
- AUPH Nasdaq
- Market Cap
- LILA 1.3B
- AUPH 1.4B
- IPO Year
- LILA N/A
- AUPH 1999
- Fundamental
- Price
- LILA $8.21
- AUPH $11.74
- Analyst Decision
- LILA Sell
- AUPH Strong Buy
- Analyst Count
- LILA 1
- AUPH 2
- Target Price
- LILA $6.50
- AUPH $13.00
- AVG Volume (30 Days)
- LILA 230.7K
- AUPH 1.9M
- Earning Date
- LILA 11-05-2025
- AUPH 11-06-2025
- Dividend Yield
- LILA N/A
- AUPH N/A
- EPS Growth
- LILA N/A
- AUPH N/A
- EPS
- LILA N/A
- AUPH 0.42
- Revenue
- LILA $4,409,700,000.00
- AUPH $260,111,000.00
- Revenue This Year
- LILA $1.37
- AUPH $17.33
- Revenue Next Year
- LILA N/A
- AUPH $14.31
- P/E Ratio
- LILA N/A
- AUPH $27.86
- Revenue Growth
- LILA N/A
- AUPH 25.59
- 52 Week Low
- LILA $4.26
- AUPH $6.55
- 52 Week High
- LILA $10.79
- AUPH $13.54
- Technical
- Relative Strength Index (RSI)
- LILA 56.09
- AUPH 46.50
- Support Level
- LILA $8.09
- AUPH $11.18
- Resistance Level
- LILA $8.49
- AUPH $11.70
- Average True Range (ATR)
- LILA 0.22
- AUPH 0.66
- MACD
- LILA -0.01
- AUPH -0.18
- Stochastic Oscillator
- LILA 50.00
- AUPH 42.50
About LILA Liberty Latin America Ltd.
Liberty Latin America Ltd is a telecommunications company. It is a provider of video, broadband internet, fixed-line telephony, and mobile services to residential and business customers. The company's reportable segments include C&W Caribbean, Liberty Networks, C&W Panama, VTR, Liberty Puerto Rico and Liberty Costa Rica. The company generates the majority of its revenue from C&W Caribbean, and Liberty Puerto Rico segments.
About AUPH Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.